The US pain management market growth continues to demonstrate resilience as the pharmaceutical sector innovates novel non-opioid analgesics that address the significant unmet need for effective chronic pain relief without addiction liability. New molecular entities targeting nerve growth factor inhibitors, voltage-gated sodium channel blockers, and cannabinoid receptor modulators are advancing...